Concepedia

Author

Julio C. C. Lorenzi

Rockefeller UniversityORCID

Also Known As

A Marini, J C C Lorenzi, J. C. C. Lorenzi, J. Lorenzi, J.C. Cetrulo Lorenzi, J.C. Lorenzi, J.C.C. Lorenzi, Julio C C Lorenzi, Julio C Cetrulo Lorenzi, Julio C. C. Lorenzi

91

Publications

12.5K

Citations

41

H-Index

76

Concepts

All Affiliations

Rockefeller UniversityHoward Hughes Medical InstituteCalifornia Institute of TechnologyBeth Israel Deaconess Medical CenterUniversidade de São Paulo
JC

About

Julio C. C. Lorenzi is an author at Rockefeller University specializing in medicine, immunology, and virology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

22

3.9K

2

Allergy

3

3

576

3

Health Sciences

1

1

26

4

Public Health

1

1

19

5

Biomolecular Engineering

1

1

50

Julio C. C. Lorenzi

×

55

Publications

12.4K

Citations

40

H-Index

YearCitations

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Davide F. Robbiani, Christian Gaebler, Frauke Muecksch,

Nature

2020

2.1K

Evolution of antibody immunity to SARS-CoV-2

Christian Gaebler, Zijun Wang, Julio C. C. Lorenzi,

Nature

2021

1.7K

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Christopher O. Barnes, Anthony P. West, Kathryn E. Huey‐Tubman,

Cell

2020

911

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

Marina Caskey, Florian Klein, Julio C. C. Lorenzi,

Nature

2015

752

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Fabian Schmidt, Yiska Weisblum, Frauke Muecksch,

The Journal of Experimental Medicine

2020

626

Combination therapy with anti-HIV-1 antibodies maintains viral suppression

Pilar Mendoza, Henning Gruell, Lilian Nogueira,

Nature

2018

523

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Zijun Wang, Julio C. C. Lorenzi, Frauke Muecksch,

Science Translational Medicine

2020

511

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

Johannes F. Scheid, Joshua A. Horwitz, Yotam Bar‐On,

Nature

2016

464

Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo

Alexandra Schäfer, Frauke Muecksch, Julio C. C. Lorenzi,

The Journal of Experimental Medicine

2020

352

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques

Masashi Shingai, Olivia K. Donau, Ronald J. Plishka,

The Journal of Experimental Medicine

2014

327

Page 1